Mustang Bio (2W6) AI Stock Analysis

Mustang Bio

(Stuttgart:2W6)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Low leverage / stronger balance sheetZero reported debt and a recovery of stockholders’ equity materially reduce solvency risk and interest burden. This improves financial flexibility to fund clinical programs or negotiate collaborations, extending runway and lowering default risk versus prior periods.

Negative Factors

Pre-revenue profileWith no product revenue, the company lacks recurring cash inflows to fund operations. Long-term viability therefore depends on future clinical success and external financing, making operational continuity vulnerable to trial setbacks or capital-market conditions.

Mustang Bio (2W6) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 2.69M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -0.9
Beta (1Y): ―
Revenue Growth: ―
EPS Growth: ―
Country: Germany
Employees: 4
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Mustang Bio Business Overview & Revenue Model

Company Description

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen...

Mustang Bio Risk Analysis

Mustang Bio disclosed 65 risk factors in its most recent earnings report. Mustang Bio reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

Mustang Bio Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:2W6 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ACXP	41Neutral	$5.78M	-0.29	-124.74%	―	―	71.66%
LYRA	41Neutral	$337.23K	-0.01	455.31%	―	-74.05%	73.08%
BOLT	40Underperform	$12.69M	-0.41	-126.23%	―	12.79%	37.93%
SLXN	40Underperform	$2.21M	-0.00	-563.11%	―	―	98.10%
XTLB	39Underperform	$7.56M	-0.56	-269.02%	―	―	―

* Healthcare Sector Average

Performance Comparison

DE:2W6 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:2W6	Mustang Bio	0.30	0.00	0.00%
XTLB	XTL Biopharmaceuticals Ltd. Sponsored ADR	1.61	-2.59	-61.67%
LYRA	Lyra Therapeutics, Inc.	0.19	-5.56	-96.70%
BOLT	Bolt Biotherapeutics, Inc.	6.59	1.01	18.10%
SLXN	Silexion Therapeutics Corp	0.14	-31.55	-99.54%
ACXP	Acurx Pharmaceuticals Llc	1.04	-4.02	-79.45%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Mustang Bio AI Stock Analysis